Alzheimer's Matters Blog

Alzheimer's Matters Blog

Alzheimer’s Matters, the official blog of the ADDF, features insights, perspectives and commentary on current topics of interest in Alzheimer’s disease and related drug discovery.

What Lithium Means For Your Brain Health


If you’re a regular reader of The New York Times, you may have a seen a recent article asking “Should We All Take a Bit of Lithium?” It’s a provocative question, inspired by the writer’s recent introduction to a collection of research showing an association between lithium exposure and “beneficial clinical, behavioral, legal and medical outcomes” including some evidence that the naturally occurring element is neuroprotective.

5 Research Highlights from the Premier Conference on Alzheimer’s Drug Discovery


Every year, the Alzheimer’s Drug Discovery Foundation (ADDF) brings leaders in academia and industry together for the only conference in the world exclusively focused on drug discovery and development for Alzheimer’s disease and related dementias. Researchers at this year’s conference showcased an unbelievable array of promising research—research that was indicative of the ADDF’s dynamic, diverse portfolio and a reflection of just how far we’ve come in our search for an effective treatment, and a cure, for Alzheimer’s disease.

New Research Suggests Drugs that “Fix” the APOE4 Risk Factor for Alzheimer’s Disease May Be Safe


Last week, The New York Times reported on new research revealing that a man without the APOE gene—a gene that helps to carry cholesterol and, in certain forms, dramatically increases a person’s risk of developing Alzheimer’s disease—was able to function normally. The news has important implications for Alzheimer’s research, suggesting that if scientists could develop therapies that inhibit the potentially toxic effects of APOE, patients could take the drug without fear of neurological complications.

Alzheimer’s Disease is the Greatest Threat to Productive Aging


By 2050, more than 1.5 billion people worldwide will be over the age of 65—triple the number of present-day seniors. And while the US ranks high on the aging populations’ scorecard, Japan, South Korea, Spain and Italy top the list. By midcentury, a third of their populations will be over 65.

Top 5 Reasons to Attend the 15th International Conference on Alzheimer’s Drug Discovery!


Just 7 days left to register for our 15th International Conference on Alzheimer’s Drug Discovery at a special early bird rate! It’s a unique opportunity to join leaders in academic and industry to learn about the latest developments in Alzheimer’s drug discovery research at a fraction of the ordinary registration costs. Need more convincing? Here are the top 5 reasons to join us on September 8th and 9th in Jersey City, NJ, for our 15th International Conference on Alzheimer’s Drug Discovery!

5 Updates From the World’s Largest Gathering of Alzheimer’s Researchers


Did you miss news from the 2014 Alzheimer’s Association International Conference (AAIC) in Copenhagen, Denmark? Not to worry—our team of neuroscientists was there in full force, and now they’re sharing highlights from their favorite sessions on our blog. 

A Must-Read for Anyone Affected by Alzheimer’s Disease


With practical advice for caregivers, important information about the state of Alzheimer’s research and a moving record of her life after losing a loved one to the disease, Joan Sutton’s powerful new memoir is at once distinctive, instructive and deeply relatable. It's a must-read for anyone who has been affected by Alzheimer's disease.

New Drug Offers Promise to Patients with Alzheimer’s


Researchers funded by the Alzheimer’s Drug Discovery Foundation have identified a promising new drug that prevents the formation of abnormal blood clots in the brain, reduces cerebral inflammation and improves memory in mice with Alzheimer’s disease. The drug, RU-505, is a synthetic compound identified from an initial pool of nearly 95,000 drug candidates.

The Difference Between Alzheimer’s Disease and Normal Cognitive Aging


A century after Alois Alzheimer described a "peculiar case" of presenile dementia, researchers know more than ever before about the biology of aging and Alzheimer’s disease. But despite incredible progress, more than 59 percent of adults still believe that Alzheimer’s disease is a typical part of aging. This widespread misconception means that many individuals are going undiagnosed and untreated, and that crucial research towards a cure is going unfunded.

An Alzheimer’s Widow Finds Hope in Drug Discovery


My husband and I had been together 26 years when he became one of nearly six million North Americans diagnosed with Alzheimer’s disease.  Seven years later, I was an Alzheimer’s widow. As useful as support groups, information booklets and other sources of information were, what I wanted more than anything during those seven years as a caregiver was a drug that would alter the course of the disease. But there is no drug that will stop Alzheimer’s from progressing. There is no cure. And there are no survivors.